Page 20 - Read Online
P. 20

Page 14                                                              Bax. J Transl Genet Genom 2020;4:1-16  I  http://dx.doi.org/10.20517/jtgg.2020.08

                   in familial MNGIE syndrome. Neurology 1998;51:1086-92.
               41.   Chapman TP, Hadley G, Fratter C, Cullen SN, Bax BE, et al. Unexplained gastrointestinal symptoms: think mitochondrial disease. Dig
                   Liver Dis 2014;46:1-8.
               42.   Scarpelli M, Russignan A, Zombor M, Bereczki C, Zappini F, et al. Poor outcome in a mitochondrial neurogastrointestinal
                   encephalomyopathy patient with a novel TYMP mutation: the need for early diagnosis. Case Rep Neurol 2012;4:248-53.
               43.   Çoban G, Göktürk S, Yildirim E, Çalışkan Z, Horasanli B, et al. Mitochondrial neurogastrointestinal encephalomyopathy: imaging and
                   clinical findings in three patients. Diagnostic Interv Radiol 2013;19:191-4.
               44.   Mueller LA, Camilleri M, Emslie-Smith AM. Mitochondrial neurogastrointestinal encephalomyopathy: manometric and diagnostic
                   features. Gastroenterology 1999;116:959-63.
               45.   Teitelbaum JE, Berde CB, Nurko S, Buonomo C, Perez-Atayde AR, et al. Diagnosis and management of MNGIE syndrome in children:
                   case report and review of the literature. J Pediatr Gastroenterol Nutr 2002;35:377-83.
               46.   Halter J, Schüpbach W, Casali C, Elhasid R, Fay K, et al. Allogeneic hematopoietic SCT as treatment option for patients with
                   mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone
                   Marrow Transplant 2011;46:330-7.
               47.   Schüpbach WMM, Vadday KM, Schaller A, Brekenfeld C, Kappeler L, et al. Mitochondrial neurogastrointestinal encephalomyopathy in
                   three siblings: clinical, genetic and neuroradiological features. J Neurol 2007;254:146-53.
               48.  Moran NF, Bain MD, Muqit MMK, Bax BE. Carrier erythrocyte entrapped thymidine phosphorylase therapy for mngie. Neurology
                   2008;71:686-8.
               49.   Laforce R Jr, Valdmanis PN, Dupré N, Rouleau GA, Turgeon AF, et al. A novel TYMP mutation in a French Canadian patient with
                   mitochondrial neurogastrointestinal encephalomyopathy. Clin Neurol Neurosurg 2009;111:691-4.
               50.   Oztas E, Ozin Y, Onder F, Onal IK, Oguz D, et al. Chronic intestinal pseudo-obstruction and neurological manifestations in early
                   adulthood: considering MNGIE syndrome in differential diagnosis. J Gastrointestin Liver Dis 2010;19:195-7.
               51.   Li JN, Han DY, Ji F, Chen AT, Wu N, et al. Successful cochlear implantation in a patient with MNGIE syndrome. Acta Otolaryngol
                   2011;131:1012-6.
               52.   Dreznik Y, Gutman M, Weiss B, Nevler A. Mitochondrial neuro-gastrointestinal encephalomyopathy presenting with recurrent bowel
                   perforations and intra-abdominal abscesses. J Gastrointest Surg 2014;18:2054-6.
               53.   Vondráčková A, Veselá K, Kratochvílová H, Kučerová Vidrová V, Vinšová K, et al. Large copy number variations in combination with
                   point mutations in the TYMP and SCO2 genes found in two patients with mitochondrial disorders. Eur J Hum Genet 2014;22:431-4.
               54.   Kalkan IH, Köksal AŞ, Evcimen S, Sapmaz F, Öztaş E, et al. Spontaneous abdominal esophageal perforation in a patient with
                   mitochondrial neurogastrointestinal encephalomyopathy. Acta Clin Belg 2015;70:44-5.
               55.   Peedikayil MC, Kagevi EI, Abufarhaneh E, Alsayed MD, Alzahrani HA. Mitochondrial neurogastrointestinal encephalomyopathy treated
                   with stem cell transplantation: A case report and review of literature. Hematol Oncol Stem Cell Ther 2015;8:85-90.
               56.   Hirano M. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. Gene Reviews (Internet). Seattle (WA): University of Washington,
                   Seattle; 1993-2020.
               57.   Scarpelli M, Ricciardi GK, Beltramello A, Zocca I, Calabria F, et al. The role of brain MRI in mitochondrial neurogastrointestinal
                   encephalomyopathy. Neuroradiol J 2013;26:520-30.
               58.   Gramegna LL, Pisano A, Testa C, Manners DN, D’Angelo R, et al. Cerebral mitochondrial microangiopathy leads to leukoencephalopathy
                   in mitochondrial neurogastrointestinal encephalopathy. Am J Neuroradiol 2018;39:427-34.
               59.   Cardaioli E, Da Pozzo P, Malfatti E, Battisti C, Gallus GN, et al. A second MNGIE patient without typical mitochondrial skeletal muscle
                   involvement. Neurol Sci 2010;31:491-4.
               60.   Yadak R, Smitt PS, van Gisbergen MW, van Til NP, de Coo IF. Mitochondrial neurogastrointestinal encephalomyopathy caused by
                   thymidine phosphorylase enzyme deficiency: from pathogenesis to emerging therapeutic options. Front Cell Neurosci 2017;11:31.
               61.   Yolcu M, Yolcu C, Kaya Z, Cakmak EO, Sezen Y. Endocarditis in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)
                   syndrome: the first in the literature. J Clin Diagn Res 2014;8:SD01-2.
               62.   Li KM, Rivory LP, Clarke SJ. Rapid quantitation of plasma 2’-deoxyuridine by high-performance liquid chromatography/atmospheric
                   pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. J Chromatogr B
                   Analyt Technol Biomed Life Sci 2005;820:121-30.
               63.   La Marca G, Malvagia S, Casetta B, Pasquini E, Pela I, et al. Pre- and post-dialysis quantitative dosage of thymidine in urine and plasma
                   of a MNGIE patient by using HPLC-ESI-MS/MS. J Mass Spectrom 2006;41:586-92.
               64.   Mohamed S, Caporali L, De Giorgio R, Carelli V, Contin M. HPLC-UV analysis of thymidine and deoxyuridine in plasma of patients
                   with thymidine phosphorylase deficiency. J Chromatogr B Analyt Technol Biomed Life Sci 2014;949-950:58-62.
               65.   Fairbanks LD, Levene M, Bax BE. Validation of a HPLC method for the measurement of erythrocyte encapsulated thymidine
                   phosphorylase (EE-TP) activity. J Pharm Biomed Anal 2013;76:8-12.
               66.   Hirano M, Garone C, Quinzii CM. CoQ 10 deficiencies and MNGIE: two treatable mitochondrial disorders. Biochim Biophys Acta
                   2012;1820:625-31.
               67.   Stenson PD, Mort M, Ball E V, Shaw K, Phillips A, et al. The human gene mutation database: building a comprehensive mutation
                   repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet 2014;133:1-9.
               68.   Pacitti D, Levene M, Garone C, Nirmalananthan N, Bax BE. Mitochondrial neurogastrointestinal encephalomyopathy: into the fourth
                   decade, what we have learned so far. Front Genet 2018;9:669.
               69. Kalkan IH, Tayfur O, Oztas E, Beyazit Y, Yildiz H, et al. A novel finding in MNGIE (mitochondrial neurogastrointestinal
   15   16   17   18   19   20   21   22   23   24   25